Aroa Biosurgery Limited

ASX:ARX Voorraadrapport

Marktkapitalisatie: AU$206.9m

Aroa Biosurgery Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Brian Ward

Algemeen directeur

NZ$1.1m

Totale compensatie

Percentage CEO-salaris54.1%
Dienstverband CEO17.2yrs
Eigendom CEO9.6%
Management gemiddelde ambtstermijn3.6yrs
Gemiddelde ambtstermijn bestuur9.8yrs

Recente managementupdates

Recent updates

Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper

Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues

Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge

Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors

Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price

We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth

Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

May 26
Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results

An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Mar 22
An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued

Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Feb 24
Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Feb 24
Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)

Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Dec 16
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 44% Above Its Share Price

Analyse CEO-vergoeding

Hoe is Brian Ward's beloning veranderd ten opzichte van Aroa Biosurgery's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2024NZ$1mNZ$583k

-NZ$11m

Dec 31 2023n/an/a

-NZ$9m

Sep 30 2023n/an/a

-NZ$8m

Jun 30 2023n/an/a

-NZ$4m

Mar 31 2023NZ$1mNZ$552k

-NZ$396k

Dec 31 2022n/an/a

-NZ$1m

Sep 30 2022n/an/a

-NZ$2m

Jun 30 2022n/an/a

-NZ$5m

Mar 31 2022NZ$1mNZ$542k

-NZ$8m

Dec 31 2021n/an/a

-NZ$10m

Sep 30 2021n/an/a

-NZ$11m

Jun 30 2021n/an/a

-NZ$15m

Mar 31 2021NZ$2mNZ$483k

-NZ$19m

Compensatie versus markt: Brian's total compensation ($USD642.92K) is above average for companies of similar size in the Australian market ($USD299.27K).

Compensatie versus inkomsten: Brian's compensation has been consistent with company performance over the past year.

CEO

Brian Ward

17.2yrs

Tenure

NZ$1,078,619

Compensatie

Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Brian Ward
Founderno dataNZ$1.08m9.6%
A$ 19.9m
James Agnew
CFO & Joint Company Secretary4.8yrsNZ$627.01kgeen gegevens
Rod Stanley
Chief Technology Officerless than a yeargeen gegevensgeen gegevens
Barnaby May
Chief Scientific Officer2.9yrsgeen gegevens0.95%
A$ 2.0m
Neetha Alex-Kumar
General Counselno datageen gegevensgeen gegevens
Frazer Murray
Director of Global Marketing & Strategyno datageen gegevensgeen gegevens
Yasmin Winchester
Vice President of Qualityno datageen gegevensgeen gegevens
Tracy Weimar
Joint Company Secretary4.3yrsgeen gegevensgeen gegevens
Adam Young
Vice President of Medical Affairsno datageen gegevensgeen gegevens

3.6yrs

Gemiddelde duur

Ervaren management: ARX's management team is considered experienced (3.6 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Brian Ward
Founder17.2yrsNZ$1.08m9.6%
A$ 19.9m
James McLean
Independent Non-Executive Chairperson13.3yrsNZ$212.19k0.82%
A$ 1.7m
John Diddams
Independent Non-Executive Director5yrsNZ$159.36k0.35%
A$ 715.5k
John Pinion
Independent Non-Executive Director9.8yrsNZ$187.52k0.14%
A$ 283.5k
Philip McCaw
Non-Executive Director16.7yrsNZ$130.68k5.68%
A$ 11.8m
Catherine Mohr
Independent Non-Executive Director2yrsNZ$178.02k0.13%
A$ 261.8k
Darla Hutton
Independent Non-Executive Directorless than a yearNZ$4.73k0.041%
A$ 84.1k

9.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: ARX's board of directors are considered experienced (9.8 years average tenure).